TP-0184

DRUG2 trials

Sponsors

Sumitomo Pharma America, Inc.

Conditions

Advanced Solid TumorsAnemia in Myelodysplastic Syndromes

Phase 1

First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors

CompletedNCT03429218

Sumitomo Pharma America, Inc.Advanced Solid Tumors

Start: 2018-07-10End: 2021-03-08Updated: 2023-11-14

A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS

TerminatedNCT04623996

Sumitomo Pharma America, Inc.Anemia in Myelodysplastic Syndromes

Start: 2020-12-28End: 2021-04-27Updated: 2023-11-09

Related Papers

Abstract CT134: Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic (PK), and pharmacodynamic study of oral TP-0184, an activin receptor-like kinase-2 (ALK2) inhibitor, in patients (pts) with advanced solid tumors (ASTs)

Cancer Research2022-06-152 citations

Phase 1/2 Study of Oral TP-0184 for the Treatment of Anemia in Adults with Low- or Intermediate-Risk Myelodysplastic Syndromes

Blood2021-11-053 citations

Abstract 3166: Evaluation of genetic modulation of <i>ACVR1</i> (aka <i>ALK2</i>) kinase gene as a clinical biomarker of the ACVR1 inhibitor TP-0184

Cancer Research2019-07-01

Abstract 3166: Evaluation of genetic modulation of<i>ACVR1</i>(aka<i>ALK2</i>) kinase gene as a clinical biomarker of the ACVR1 inhibitor TP-0184

Clinical Research (Excluding Clinical Trials)2019-07-01